Key points from article :
BioAge Labs, a biotech company focused on metabolic diseases, has filed for an initial public offering (IPO) after raising $170 million earlier this year. Partnered with Eli Lilly, BioAge plans to list on the Nasdaq under the symbol “BIOA,” but hasn't disclosed how much it aims to raise through the IPO.
The company's lead drug candidate, azelaprag, will begin phase 2 trials next year. Azelaprag is designed to work alongside semaglutide, a popular weight-loss drug, to enhance weight loss while preserving muscle mass. Early studies have shown it to be well-tolerated in human trials. BioAge is also conducting trials combining azelaprag with Eli Lilly's diabetes and weight-loss drug, tirzepatide, with results expected in 2025.
In addition to its obesity trials, BioAge is developing an NLRP3 inhibitor for treating metabolic diseases and neuroinflammation, with hopes to begin human trials in 2025. The company’s IPO may be influenced by the current market interest in obesity treatments, potentially drawing more investment to the biotech sector.
